United Therapeutics Corporation Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31)
United Therapeutics Corporation (UTHR) had Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31) of $550.86 million as of 2013-06-30, per its 10-Q filed 2013-07-25.
Discontinued › Notes
us-gaap:HeldToMaturitySecuritiesDebtMaturitiesFairValue · last filed 2013-07-25
- 2013-06-30: Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31) $550.86M.
- 2013-03-31: Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31) $614.52M.
- 2012-12-31: Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31) $630.70M.
- 2012-09-30: Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31) $488.90M.
| Period end | Held-to-maturity Securities, Debt Maturities, Fair Value (Deprecated 2013-01-31) |
|---|---|
| 2013-06-30 | $550.86M 10-Q · filed 2013-07-25 |
| 2013-03-31 | $614.52M 10-Q · filed 2013-04-25 |
| 2012-12-31 | $630.70M 10-K · filed 2013-02-26 |
| 2012-09-30 | $488.90M 10-Q · filed 2012-11-01 |
| 2012-06-30 | $544.07M 10-Q · filed 2012-07-26 |
| 2012-03-31 | $588.93M 10-Q · filed 2012-04-26 |
| 2011-12-31 | $583.98M 10-K · filed 2012-02-28 |
| 2011-09-30 | $599.92M 10-Q · filed 2011-10-27 |
| 2011-06-30 | $566.09M 10-Q · filed 2011-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |